We are at a critical juncture in the pandemic: an increasing portion of the population has been vaccinated and the economy is beginning to snap back, but new variants and the long-term effects of Covid may threaten these hard-won successes.
Led by CNBC’s anchors and reporters, this CNBC Healthy Returns Summit will take stock of all that we have learned over the past 15 months – from vaccines to health equity and mental health – and apply it to future treatments and innovations. It will also look at the new ideas and breakthroughs on the horizon that are sure to transform the health care industry for years to come.
WHO SHOULD ATTEND: Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.
Watch our 2020 Event Highlights
Visit cnbc.com/healthy-returns to find in-depth coverage from the CNBC team about health care innovation.
Rochelle P. Walensky, MD, MPH, is the 19th Director of the Centers for Disease Control and Prevention and the ninth Administrator of the Agency for Toxic Substances and Disease Registry. She is an influential scholar whose pioneering research has helped advance the national and global response to HIV/AIDS. Dr. Walensky is also a well-respected expert on the value of testing and treatment of deadly viruses.
Dr. Walensky served as Chief of the Division of Infectious Diseases at Massachusetts General Hospital from 2017-2020 and Professor of Medicine at Harvard Medical School from 2012-2020. She served on the frontline of the COVID-19 pandemic and conducted research on vaccine delivery and strategies to reach underserved communities.
Dr. Walensky is recognized internationally for her work to improve HIV screening and care in South Africa and nationally recognized for motivating health policy and informing clinical trial design and evaluation in a variety of settings.
She is a past Chair of the Office of AIDS Research Advisory Council at the National Institutes of Health, Chair-elect of the HIV Medical Association, and previously served as an advisor to both the World Health Organization and the Joint United Nations Programme on HIV/AIDS.
Originally from Maryland, Dr. Walensky received her Bachelor of Arts from Washington University in St. Louis, her Doctor of Medicine from the Johns Hopkins School of Medicine, and her Masters in Public Health from the Harvard School of Public Health.
Kathrin U. Jansen, PhD, is Senior Vice President and Head of Vaccine Research and Development at Pfizer Inc, and a member of Pfizer’s Worldwide Research and Development leadership team. Dr. Jansen oversees a fully integrated, global vaccines research and development organization, with responsibilities ranging from discovery to registration and post-marketing commitments of first-in-class or best-in-class vaccines to prevent or treat diseases of significant unmet medical need. More recent accomplishments are the global licensures of Prev(e)nar13® to prevent pneumococcal diseases and the development and licensure of Trumenba®, the first vaccine licensed in the United States to prevent invasive disease caused by Neisseria meningitidis serogroup B. Dr. Jansen received her doctoral degree in microbiology, biochemistry & genetics from Phillips Universitaet, Marburg, Germany. Following completion of her formal training, she continued her postdoctoral training at Cornell University working on the structure and function of the acetylcholine receptor. She then joined the Glaxo Institute for Molecular Biology in Geneva, Switzerland, where she focused on basic studies of a receptor believed to be a drug target to treat allergies. Dr. Jansen was appointed an Adjunct Professor at the University of Pennsylvania – School of Medicine in 2010. Before the Wyeth acquisition by Pfizer in 2009, Dr. Jansen served as Senior Vice President at Wyeth Pharmaceuticals and on Wyeth’s Research and Development Executive Committee since 2006 and was responsible for vaccine discovery, early development and clinical testing operations. Dr. Jansen also briefly worked at Vaxgen as Chief Scientific Officer and Senior Vice President for Research and Development with responsibility for the company’s late stage development programs. Prior to joining Vaxgen, Dr. Jansen spent 12 years at Merck Research Laboratories where she directed or supported a number of vaccine efforts, including Merck’s novel bacterial vaccine programs and viral vaccine programs (rotavirus, zoster and mumps, measles and rubella). Dr. Jansen initiated and led the development of Gardasil®, the world’s first cervical cancer vaccine.
Dave Ricks is chairman and chief executive officer of Eli Lilly and Company. He became CEO in January 2017 and was elected chairman of the company’s board effective June 2017.
A Lilly veteran for more than 20 years, Dave served as president of Lilly Bio-Medicines from 2012 to 2016. Previously, he was president of Lilly USA, the company’s largest affiliate, from 2009 to 2012. He served as president and general manager of Lilly China, operating in one of the world’s fastest-growing emerging markets, from 2008 to 2009. And he was general manager of Lilly Canada from 2005 to 2008, after roles as director of pharmaceutical marketing and national sales director in that country. Dave joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving to Lilly Canada.
Dave earned a bachelor of science degree from Purdue University in 1990 and a master of business administration degree from Indiana University in 1996.
Dave is on the board of Adobe and is chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). He also serves on the board of the Central Indiana Corporate Partnership. Dave is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). He serves on the Riley Children’s Foundation’s board of governors.
Dr. Elaine Batchlor is the chief executive officer of Martin Luther King, Jr. Community Hospital, which opened in 2015. Dr. Batchlor was the driving force behind the effort to open the new, state-of-the-art, community-oriented, safety-net hospital providing compassionate, quality care and improving the health of the South Los Angeles community.
Throughout her career, Dr. Batchlor’s number one priority has been to improve access and quality of care for underserved communities utilizing innovative and collaborative approaches. Her work to increase access for underserved populations has been recognized as an example of leading best practices and adopted throughout California.
Before assuming the helm of Martin Luther King, Jr. Community Hospital, Dr. Batchlor served on the executive leadership team of L.A. Care Health Plan, the nation’s largest public health plan. As chief medical officer, she was instrumental in developing a care delivery model that expanded access and resources to more than a million individuals throughout the county.
She spearheaded provider use of information technology and telemedicine to improve access and quality of care for Los Angeles County’s Medi-Cal (Medicaid) population. Under her leadership, L.A. Care established the Health Information Technology Extension Center, becoming the second health plan in the nation to operate a Regional Extension Center to help safety-net providers adopt and use electronic health records. She implemented eConsult, an innovative electronic physician-to-specialist consultation and referral system, for Los Angeles County community health centers and the Los Angeles County Department of Health Services.
Prior to L.A. Care, Dr. Batchlor served in leadership positions at the California HealthCare Foundation, the Los Angeles County Department of Health Services, Prudential Health Care, and Ross Loos Medical Group. Early in her career she served as a clinical instructor at the UCLA School of Medicine.
Dr. Batchlor is an active community volunteer, serving on multiple community and healthcare boards. She has a particular interest in mentoring youth. She regularly meets with students, from high school through professional school, who are interested in careers in healthcare. Formerly, she served on advisory boards for the UCLA Fielding School of Public Health, the UCLA National Clinical Scholars, and the UCLA Academic Advancement Program Advisory Council. Recently, she was elected to the National Academy of Medicine, an academy committed to the health for all by advancing science, accelerating health equity, and providing independent, authoritative, and trusted advice nationally and globally. A Harvard alumna, Dr. Batchlor serves as an interviewer for Harvard College applicants and as a liaison to a local high school.
She served as the past chair and is currently on the board of the Integrated Healthcare Association. She is a member of the Board of Trustees of the California Association of Hospitals and Health Systems, the boards of directors of the Healthcare Quality Institute and California Health and Wellness, and the editorial board of Health Affairs, the leading peer-reviewed journal of health policy thought and research.
Dr. Batchlor received a Bachelor of Arts degree from Harvard University, a Master of Public Health degree from the University of California, Los Angeles, and a Doctorate in Medicine degree from Case Western Reserve University. She completed internship, residency, and fellowship training in internal medicine and rheumatology at Harbor-UCLA Medical Center and is board-certified in both specialties.
She is married to a lawyer who has spent his career representing indigent clients, currently working for the Los Angeles County Public Defender’s Office. The couple has twin boys.
12:00pm ET
Covid Latest: Vaccinations, Variants and the Mission to Reopen the Country
While Americans are being vaccinated at record pace, the pause of the Johnson& Johnson vaccine and the rise of new variants run the risk of putting the country off the path of reopening. CDC Director Dr. Rochelle Walensky joins us to give us the latest news on Covid and when she thinks it’ll be safe to reopen.
Dr. Rochelle P. Walensky, Centers for Disease Control and Prevention Director
Interviewer: Meg Tirrell, CNBC Senior Health & Science Reporter
Watch the full interview
Investor’s Playbook: Game-Changing Startups
At the height of the pandemic, the biotech industry saw an unprecedented level of investment activity. And there is no sign of a slowdown. Former Google Ventures CEO Bill Maris gives us a peek at his playbook and explains which disruptive life science technologies – from microsurgical robotics and precision medicines to genomics and therapeutics– are successfully tackling humanity’s most complex conditions.
Bill Maris, Section 32 Founder
Interviewer: Melissa Lee, CNBC “Fast Money” and “Options Action” Host
Watch the full interview
12:40pm ET
Transforming Health Care
At the forefront of developing Covid-19 antibodies, Eli Lilly has doubled down on R&D, digital analytics and medical innovation. With a pipeline of new drugs in the works to treat conditions ranging from Alzheimer’s to diabetes to migraines, they are focusing hard on finding new ways to collaborate with partners and governments to deliver groundbreaking treatments in record time.
David Ricks, Eli Lilly Chairman and CEO
Interviewer: Meg Tirrell, CNBC Senior Health & Science Reporter
Watch the full interview
Driving Transparency in Healthcare with Embedded AI
Sponsored and programmed by Change Healthcare
The journey in and around Artificial Intelligence is complicated, but the technology can reshape the healthcare industry for both providers and consumers by helping create solutions, simplify processes, and answer questions that were previously unknown. In this session, we will examine how an API Marketplace can drive transparency and provide access to critical data.
Steven Martin, Change Healthcare EVP Enterprise Technology
Interviewer: Rhonda Schaffler, Business Journalist
Innovative Thinking to Fight Inequality
The toll of the pandemic is nowhere clearer than inside the halls of MLK Community Hospital, which serves the most economically depressed people in Covid-ravaged Los Angeles. One visionary hospital leader is taking a page out of Silicon Valley and using innovation to put an end to unequal systems of care.
Dr. Elaine Batchlor, Martin Luther King, Jr. Community Hospital CEO
Interviewer: Tyler Mathisen, “Power Lunch” Co-Anchor & Vice President, Events Strategy
Watch the full interview
Mission Critical for Mental Health and Caring for All
Earlier this year, insurer Centene announced it will purchase Magellan Health to integrate behavioral health into overall plans for its customers. Centene CEO Michael Neidorff discusses how this may change health plans and treatments for a broader group of people.
Michael Neidorff, Centene CEO
Interviewer: Bertha Coombs, CNBC Reporter
Watch the full interview
1:35pm ET
Big bets on Biotech
Over the past decade, Blackstone has invested nearly $17 Billion in medicines, therapeutics and health care technologies. Its competitive advantage: A one-stop shop for emerging biotechs looking to scale their business. We will learn how one of the world’s largest investors uses its broad financial platforms to deliver unique solutions to the most promising health innovations
Nicholas Galakatos, Blackstone Life Sciences Global Head
Interviewer: Morgan Brennan, CNBC “Squawk on the Street” Co-Anchor
Watch the full interview
Health Equity for All
The Covid-19 pandemic exposed a wide array of racial and socio-economic disparities in health care. We’ll examine one New York hospital on the front lines as a case study, reflect on the lessons learned, and discuss actionable steps every provider should take now to move toward a more equitable future.
Dr. Steven Corwin, NewYork-Presbyterian Hospital CEO
Dr. Julia Iyasere, NewYork-Presbyterian Dalio Center for Health Justice Executive Director
Moderator: Sharon Epperson, CNBC Senior Correspondent
Watch the full interview
Reimagining Healthcare: Putting Prevention Over Cure
Sponsored and programmed by Babylon
The pandemic has been an important inflection point for the healthcare industry and presented an opportunity to create impactful and lasting change. It has exposed the flaws in our current healthcare system and the detriments of reactive healthcare. The session will explore why the industry needs to rethink its approach in favor of proactive, preventative medicine, utilizing technology at the heart of a new health ecosystem, in order to improve the system long-term for both patients and providers.
Molly Joseph, Cypress Pass Ventures Managing Partner
Ali Parsa, Babylon CEO
Moderator: Jen Rogers, Financial Reporter
2:00pm ET
The Future of Virtual Care for Behavioral Health
Sponsored and programmed by Ontrak
Covid-19 upended an already burdened health care system, especially for mental health and substance abuse services that were already experiencing a shortage of providers. With behavioral health disorders continuing to rise in the aftermath of the pandemic, a new crisis is taking shape. This session will examine the future of virtual care and why success hinges on a collaborative, behavioral health-focused approach.
Jonathan Mayhew, Ontrak CEO
Interviewer: Caroline Woods, Business Journalist
Behind the Scenes of Developing Vaccines
Pfizer turned the impossible into possible, creating a groundbreaking Covid-19 vaccine in record time. Leading the charge was Kathrin Jansen, who will take us behind-the-scenes of this massive undertaking and share lessons in efficiency and leadership.
Kathrin Jansen, Pfizer SVP, Head of Vaccine R&D
Interviewer: Meg Tirrell, CNBC Senior Health and Science Reporter
Watch the full interview
Commercializing Science
A molecular biologist by training, and longtime Harvard Business School Professor, Sato has spent decades guiding businesses, research institutions, universities, aspiring entrepreneurs and municipalities on how to create and build world-class biotech ecosystems from the ground up.
Vicki Sato, Vir Biotechnology and Denali Therapeutics, Chairman of the Board of Directors
Interviewer: Deirdre Bosa, CNBC “TechCheck” Co-Anchor
Watch the full interview
2:40pm ET
Next Frontier in Treating Mental Health: Psychedelics
Psychedelics have been highly stigmatized, and highly restricted, for nearly a century. Now, renewed interest has given way to robust research, to identify their potential as treatment for conditions like depression, addiction, and trauma. One former NHL star shares his personal story of transformation. And we’ll examine whether psychedelics have the potential to go mainstream and disrupt the drug industry.
Daniel Carcillo, Wesana Health CEO, Former NHL Player
Dr. Sharmin Ghaznavi, Mass General Hospital Assoc. Director, Center for the Neuroscience of Psychedelics
Kevin O’Leary, “Shark Tank” Co-Host & O’Shares ETFs Chairman
Interviewer: Dom Chu, CNBC Senior Markets Correspondent
Watch the full interview
The Future of Medicine: Telehealth
The boom of phone and video appointments during the pandemic ushered in a new era of telemedicine. We’ll discuss the rapid rise with the most dominant player in the industry and examine how telemedicine will evolve post-Covid.
Jason Gorevic, Teladoc CEO
Interviewer: Bertha Coombs, CNBC Reporter
Watch the full interview
Pandemic Playbook: Predict. Prevent. Prepare.
Three leading visionaries in the fields of medicine, Artificial Intelligence for health and philanthropy explain how collaboration and data science can advance the prevention, diagnoses and treatment to some of the world’s most difficult health challenges.
Dr. John Halamka, Mayo Clinic Platform President
Peter Lee, Microsoft Research and Incubations Corporate Vice President
Interviewer: Sharon Epperson, CNBC Senior Correspondent
Watch the full interview
The Big Test: How Abbott is Applying Pandemic Learnings to the Future
Abbott Labs has been at the forefront of testing from the earliest days of the pandemic. And now, as the world begins to reopen, testing will continue to be critical to the success of the recovery. Abbott CEO Robert Ford joins us to discuss the current state of testing, lessons learned from the past year and a half, and how those learnings may translate into innovation and accelerated execution for future products.
Robert Ford, Abbott Chief Executive Officer
Interviewer: Jim Cramer, CNBC Host of “Mad Money w/ Jim Cramer” & Co-Anchor “Squawk on the Street”
Watch the full interview
4:00pm ET
Registration for our Summit is now closed. Please email events@cnbc.com to connect with our audience team.
Subscribe to our Healthy Returns newsletter for exclusive insights on the biggest health care news from our reporters, delivered straight to your inbox every Friday.
You can also visit cnbc.com/healthy-returns for relevant content from the event and all-things health care investing and innovation.
Babylon is creating a better model of healthcare for everyone. Babylon is the leading, digital-first, global value based care provider whose mission is to make high-quality healthcare accessible and affordable for everyone on Earth. We are reengineering healthcare, shifting the main focus from sick to preventative care resulting in better health and reduced costs. We do this by leveraging a highly scalable, digital-first platform combined with best-in-class, virtual clinical operations to provide all-in-one, personalized healthcare.
Visit babylonhealth.com/us.
Change Healthcare is a leading independent healthcare technology company, focused on insights, innovation and accelerating the transformation of the healthcare system through the power of the Change Healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.
Our platform and comprehensive suite of software, analytics, technology enabled services and network solutions drive improved results in the complex workflows of healthcare system payers and providers by enhancing clinical decision making, simplifying billing, collection and payment processes, and enabling a better patient experience.
Our Intelligent Healthcare Network is one of the largest clinical and financial healthcare networks in the U.S., facilitating over 15 billion transactions and approximately $1.5 trillion in adjudicated claims, or more than one-third of all U.S. healthcare expenditures. Our customer base includes approximately 2,400 government and commercial payer connections, 1,000,000 physicians, 125,000 dentists, 39,000 pharmacies, 6,000 hospitals and 700 laboratories.
Ontrak is a leading AI and telehealth enabled behavioral health company with programs that leverage advanced analytics combined with human connection to identify, engage, guide-to-treatment and activate complex, hard-to-reach populations with unaddressed behavioral conditions and co-existing chronic medical conditions. Ontrak offers up to 52 weeks of a coach-driven, therapist-led behavior change program that engages members using an evidence-based, whole-person approach, delivering durable outcomes and validated cost savings to healthcare payers.
Visit www.ontrak-inc.com.
As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.
Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.
From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.
Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.
He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.
The developer of a comprehensive, patient-centric electronic medical record (EMR) system and founder of Epic Systems Corporation, Judith Faulkner is recognized for her scientific and technological leadership. Her vision for health care technology is both comprehensive and simple: provide the relevant medical information when it's needed, do what's best for the patient, and help clinicians collaborate. Her innovative health information technology infrastructure allows for the implementation of workflow steps, clinical guidelines, and best-practice alerts tailored to each clinician's role in patient care while on the patient end providing information regarding prescriptions, appointments, communication with the care team, and prevention/treatment reminders.
Epic EMR systems do away with traditional paper files and provide a single, shared patient record which can be accessed by clinical staff across all manner of health care services and, with proper consent, across different health care organizations. Given the complexity and magnitude of medical data that may be included, the technological challenge has been to develop this comprehensive infrastructure for diverse health care settings while scaling to millions of records and thousands of concurrent users who all require rapid response times.
Independent studies have documented the positive impact of Epic technologies on the quality of clinical care and the software has led to improvements in medical research. To date, 240 health care organizations use Epic technologies to provide medical care to approximately 118 million people. This includes fourteen Wisconsin organizations that increasingly serve as the early adopters of the latest advances in Epic's health technologies.
Faulkner has led Epic strategically and operationally to create state-of-the-art technologies that improve the quality, safety, and efficiency of health care across Wisconsin, the United States, and, increasingly, the world.
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Indigo. He is currently a Venture Partner at Flagship Pioneering. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer at Merck & Co., Inc., where she is responsible for a broad portfolio focused on patient engagement, strategic communications, global public policy, population health and corporate responsibility. She joined Merck in 2010 as president of Merck vaccines
Previously, Dr. Gerberding was Director of the U.S. CDC, where she led the agency through 40+ emergency responses to public health crises. She serves on the Boards of Biotechnology Innovation Organization (BIO), Cerner Corporation and the MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries.
Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. In 2018, she was selected as the Healthcare Businesswomen Association’s Woman of the Year and received the Lifetime Achievement Award from eyeforpharma.
Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine. Dr. Gerberding received a Masters of Public Health at the University of California, Berkeley. She is a member of the National Academy of Medicine and a fellow of the Infectious Diseases Society of America and the American College of Physicians. She is board certified in Internal Medicine and Infectious Diseases.